Small Cap Feast

Small Cap Feast – 16 May 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 896

Total number of AIM Companies trading: 824*
* As at 14 May 2019

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): 89*

Total number of NEX Growth Market Companies trading: 87*
* As at 14 May 2019

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): 161*

Total number of Standard List Companies trading: 140*
* As at 14 May 2019

Dish of the Day:

No Joiners Today

Off the Menu:

Footasylum has left AIM following a takeover by JD Sports Fashion

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

Main Market (Premium)

Jewel UK Midco Limited, the parent company of The Watches of Switzerland Group Limited, is looking to join the premium segment of the main market. Offer TBC, expect TBC

Main Market (Standard)

IMC Exploration Group (NEX: IMCP), focused on acquiring and exploring prospecting licence areas which have high potential for natural resource, is looking to admit its shares to the standard list and will withdraw for the NEX Exchange. Expected 11 June 2019

Pure Gold—  TSX listed seeking a London listing. Focused on Madsen Red Lake Gold Deposit.  Feasibility Study outlines a robust 12-year, high grade, 800 tonne per day underground mining operation with low initial capital cost of C$95mm and strong financial performance with an after-tax NPV of C$247mm . Introduction only at this point Mkt cap CA£138m.

Main Market (Specialist Funds)

Riverstone Credit Opportunities Income  – raising US$200m—will seek to generate consistent shareholder returns predominantly in the form of income distributions principally by making senior secured loans to energy-related businesses. Due 24 May

AIM

Essensys plc—a provider of mission-critical SaaS platforms and on-demand cloud services to the high growth flexible workspace industry, plans to join AIM. Offer TBC,  expected 29 May 2019.

Induction Healthcare Group plc—a healthcare technology company focused on streamlining the delivery of care by Healthcare Professionals looking to join AIM. Expected raise of £14.58m at 115p, market cap of £34.07m. Expected 22 May 2019.

SDX Energy plc—a North Africa focused oil and gas company, announces its intention to complete a Canadian plan of arrangement under section 192 of the Canada Business Corporations Act and will have shares de-listed from the TSX-V and admitted to trading on AIM. Expected 28 May 2019, anticipated market cap of £76m

Renold plc—a leading international supplier of industrial chains and related power transmission products, announced that it will cancel the listing of the Company from the premium segment and apply for admission on AIM. Expected 06 June 2019.

Alumasc Group plc, the premium building products, systems and solutions group, has announced its intention to move from the Premium Segment of the main market to AIM. Expected market cap of £33.4m. Expected 25 June 2019

Nex Exchange

SSuINOx—has developed a hydrocarbon fuels conditioning and emulsifying process that enables more efficient fuel combustion, leading potentially to reduced fuel usage and significantly lowered emissions.  Offer TBA.

Rumours and Speculation

According to Reuters — Walmart, the world’s biggest retailer, said it is considering a stock market listing for its British supermarket arm Asda, whose attempt to combine with rival Sainsbury’s was blocked by the UK regulator last month.

Breakfast Buffet

Sareum Holdings* (SAR.L) 0.7p £18.69m

Sierra Oncology (the licence holder for Chk1 inhibitor SRA737) updated in relation to presentations of preliminary clinical data from its Phase 1/2 SRA737 monotherapy study and its Phase 1/2 study of SRA737 in combination with low dose gemcitabine (SRA737+LDG) at the upcoming 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO). SRA737 monotherapy: the MTD (maximum tolerated dose) was 1000 mg/day and based on overall tolerability and PK, the recommended Phase 2 dose is 800 mg/day. The successful enrolment of prospectively-selected genetically-defined subjects will allow response data to be correlated with genomic profiles hypothesized to confer sensitivity to Chk1 inhibition. The combination of LDG and SRA737 has  been well tolerated. This first-in-human clinical study provides proof-of-concept that sub-therapeutic LDG effectively potentiates SRA737. This novel replication stress-targeted therapy warrants further evaluation in genetically pre-defined solid tumors.

 

MySale Group (MYSL.L) 11p £18.8m

MySale Group, the leading international online retailer, announced that the transaction to sell the trade and assets of the website cocosa.co.uk (“the Business”) to Brandalley UK Limited, as previously announced on 3 May 2019, has now been completed.

The Business, although only approximately 5% of total revenue, was the group’s main trading website in the UK and this disposal forms part of the rationalisation programme which will increase the group’s focus on the Australian and New Zealand (ANZ) markets.

Whilst current trading continues to be very challenging the group remains focused on reducing its cost base and through its ‘ANZ First’ strategy, utilise the group’s scale, resources and market position in the region to deliver the e-commerce platform of choice to domestic and international brands

Seeing Machines (SEE.L) 3.27p £108.5m

“The advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, provided a comprehensive update on its Fleet business.

The success of the Fleet business and its implementation of Guardian 24/7 monitoring services is fundamental to Seeing Machines. At 30 April 2019, more than 1,500 Guardian units have been installed since 31 Jan 2019, with over 14,500 units now installed in vehicles globally. This recent momentum has strengthened as the Guardian installation rate continues to accelerate with expectations that the Group will reach 16,000 Guardian units connected by 30 June 2019 and approximately 27,000 Guardian units connected by June 2020, which the Group remains on track to achieve.”

 

Belvoir Lettings (BLV.L) 117.5p £41.05m

AGM Statement form the UK’s largest property franchise.

“The Board reported that trading during the first quarter of the current financial year has been robust. Belvoir is outperforming the three key markets in which it operates, namely residential lettings, property sales and financial services. Growth in Management Service Fees (“MSF”) from lettings of 6.3% was noticeably ahead of the reported year-on-year rental index of 1.2%, growth of 10.3% from sales MSF compared with a drop of 1.5% in property transactions, and net banking from financial services (on a like-for-like basis) was up 20%.

Consequently, the Board is confident of meeting market expectations for the year ending Dec 2019.”

After 24 years of service, Mike Goddard, Belvoir’s founder and the non-executive Chairman retiring from the Board. Michael Stoop, who was appointed as a non-executive to the Board in March 2018 takes over the role of Chairman.

 

LiDCO (LID.L) 4.8p £9.77m

“AGM Statement from the hemodynamic monitoring company. LiDCO has made a good start to the year with Q1 revenues well ahead of Q1 last year and above the Board’s expectations.

In the first quarter, LiDCO product revenues were up 38% versus prior year with like-for-like recurring revenues up 42%. Recurring revenues continue to benefit from the Group’s unique, differentiated, High Usage Programme (‘HUP’) business model. At a geographical level, the US revenues, which the Board expect to be the main strategic driver of future growth, were up 69% in the quarter compared with Q1 last year. LiDCO UK revenues, excluding 3rd party products, were up 12% for the quarter.”

 

IndigoVision Group (IND.L) 180p £13.56m

“IndigoVision reports that, in the four months to 27 April 2019, trading was in line with market expectations. 

As in previous years, sales are expected to be weighted towards the second half of the year and the nature of our business is such that the precise timing of our orders is difficult to predict. Nevertheless, the current indicators support the Board’s target to return the Company to profitability in the current year.”

 

Ergomed (ERGO.L) 231p £94.49m

The company focused on providing specialised services to the pharmaceutical industry, today announces an update on trading for 2019. Trading year to date has been strong in both the Clinical Research Organisation Services (“CRO”) and pharmacovigilance (“PV”) businesses. The CRO business in particular has benefited from agreements with clients on change orders and projects concluding positively. Trading in PV remains solid and management expects this performance to be sustained throughout 2019.

Ergomed now expects revenue and EBITDA for FYDec19 to be materially above current market expectations.

 

4d Pharma (DDDD.L) 108p £68.77m

The pharmaceutical company focusing on the development of Live Biotherapeutics, announced that data from the completed Phase Ib clinical study of Thetanix®for the treatment of Crohn’s disease will be presented on 18 May in a poster session at the 2019 Digestive Disease Week meeting in San Diego. The poster was nominated as a “Poster of Distinction” within the top 10% of posters submitted to the congress. The Company has previously announced the top-line results from this study.

This study met its primary objective, demonstrating that Thetanix® was well tolerated with a good safety profile.

 

AfriAG Global (NEX:AFRI) 0.08p £1.4m

AfriAG has entered into a conditional subscription agreement to subscribe for shares in Apollon Formularies. Aggregate investment of £700k.

The first £300k proposed investment in to Apollon will be targeted towards opening Apollon’s first revenue generation businesses at Doc’s Place Wellness Center and Apollon’s first dispensary and processing facility in Negril, Jamaica and will secure the option to acquire 660 acres of prime agricultural land for future cultivation expansion.

 

Aeorema Comms (AEO.L) 28p £2.4m

The live events agency, reports a trading update for the 2019 financial year to date.

In this difficult trading environment, the Company is pleased to have secured business wins with both new and existing clients, including a three-year contract with a global media company. Aeorema has seen strong trading in the second half of the reporting period to date, with record revenues generated that will exceed those expected by the market. The new business wins, albeit on reduced margins from certain areas of client business, have contributed to the improved performance over that seen in the first half of the financial year and this will result in the Company reporting profits for the year ended 30 June 2019 broadly in line with market expectations. The Company is in a strong cash position and it remains the intention to pay a full year dividend, subject to the final audited results for the year.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.